AB0543 CHARACTERISTICS AND TREATMENT CHANGES IN PATIENTS WITH PSORIATIC ARTHRITIS SEEN IN A COMBINED DERMATOLOGY-RHEUMATOLOGY CLINIC
| Autor: | Christos Koutsianas, Dimitrios Vassilopoulos, Antonios Panagiotopoulos, Alexander J. Stratigos, P. Panagakis, Kalliopi Klavdianou, M. Stavropoulou, M. Papoutsaki, Dimitrios Rigopoulos |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
business.industry Immunology Enthesitis medicine.disease Systemic therapy General Biochemistry Genetics and Molecular Biology Dactylitis Psoriatic arthritis Rheumatology Rheumatology clinic Internal medicine Psoriasis medicine Immunology and Allergy Outpatient clinic medicine.symptom Prospective cohort study business |
| Zdroj: | Annals of the Rheumatic Diseases. 80:1304.1-1304 |
| ISSN: | 1468-2060 0003-4967 |
| Popis: | Background:Data on patients with Psoriasis (PSO) referred to a combined Dermatology-Rheumatology outpatient Clinic (Derm-Rheum) with suspected psoriatic arthritis (PsA) are limited.Objectives:To assess patient characteristics and treatment changes in PsA patients referred to a Derm-Rheum Clinic.Methods:Prospective study of PSO patients referred to a combined Derm - Rheum Clinic from February 2018 to June 2020 in a Tertiary University Hospital.Results:Among 151 patients with PSO referred to the Clinic, 129 (85%) with a final diagnosis of PsA were included. In 73% of patients (n=94) PsA was diagnosed there for the 1st time. 56% were females with a mean age of 55 years and a median disease duration of 14.2 years. At initial evaluation, 95% had peripheral arthritis, 45% nail involvement, 23% axial involvement, 12% enthesitis and 6% dactylitis with a median DAPSA score of 20.5 and PASI score of 1.6, respectively. 31% of the patients were not receiving any systemic treatment, 45% were on biologics (30% as monotherapy, 15% in combination with non-biologics), 29% were on non-biologics (14% as monotherapy, 15% in combination with biologics or targeted synthetic agents] and 10% were on targeted synthetic (ts) agents. At last visit (median follow-up: 15 months) only 8% did not receive any systemic therapy (pst visit), 62% were on biologics (39% monotherapy – 23% in combination with non-biologics, p=0.009), 46% were on non-biologics (20% as monotherapy – 26% in combination with biologics or ts agents, p=0.01) and 10% of the patients were on apremilast. The median DAPSA and PASI scores at last visit were 5.3 and 0, respectively.Conclusion:About 2/3 of patients with PSO referred to a combined Derm - Rheum Clinic with suspicious musculoskeletal complaints were diagnosed for the 1st time as PsA. During follow-up the percentage of PsA patients who started or continued systemic therapy significantly increased with significant improvement of disease activity indices. These data emphasize the value of combined Derm - Rheum Clinics for earlier diagnosis and more efficacious treatment of PsA patients.Acknowledgements:This work was supported by research grants from the Special Account for Research Grants (S.A.R.G.), National and Kapodistrian University of Athens, Athens, Greece.Disclosure of Interests:None declared. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|